Policy

BIO advocates for laws, funding and other governmental actions that ensure that biotechnology companies are able to focus on their research whether it be developing next-generation drugs, the next major advancement in agriculture or fuel to move the world...

Press Releases

BIO Statement on Most Favored Nation

September 30, 2025

WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on Most Favored Nation policies:"For too many years, Americans have subsidized the research and development necessary to bring newer and…

BIO Statement on Industry Tariffs

September 26, 2025

WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on the potential for 100% tariffs on branded or patented medicines in the US:“We share the Administration’s goals for accelerating the onshoring of…

BIO Extends Agreement with Avantor for Five Additional Years.

September 17, 2025

Collaboration maximizes BIO members’ access to Avantor’s market-leading portfolio of products, materials, and services to accelerate scientific innovation. WASHINGTON, D.C., September 17, 2025 - The Biotechnology Innovation Organization (BIO) today announced it has extended its agreement with…

BIO Advocacy Toolkit

We’ve made it easier for you to access information and share content about biotechnology and prescription medicines. Learn more about dozens of topics and then share information you discover on Twitter, Facebook, and LinkedIn.

Discover More

Become an Advocate for Biotechnology

Sign-up to join BIOAction, BIO's grassroots advocacy program. You will be notified about relevant policy issues where we need you to contact your lawmaker.

Intellectual Property